Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 176 EUR -0.23% Market Closed
Market Cap: 13.2B EUR
Have any thoughts about
Sartorius AG?
Write Note

Sartorius AG
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sartorius AG
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius AG
XETRA:SRT
Gross Profit
€1.5B
CAGR 3-Years
-5%
CAGR 5-Years
10%
CAGR 10-Years
15%
Carl Zeiss Meditec AG
XETRA:AFX
Gross Profit
€1.1B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
9%
Stratec SE
XETRA:SBS
Gross Profit
€67.8m
CAGR 3-Years
-9%
CAGR 5-Years
6%
CAGR 10-Years
3%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Gross Profit
€206.4m
CAGR 3-Years
29%
CAGR 5-Years
19%
CAGR 10-Years
13%
Siemens Healthineers AG
XETRA:SHL
Gross Profit
€8.4B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Gross Profit
€1.5B
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
3%
No Stocks Found

Sartorius AG
Glance View

Market Cap
12.1B EUR
Industry
Health Care

Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.

SRT Intrinsic Value
184.25 EUR
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Sartorius AG's Gross Profit?
Gross Profit
1.5B EUR

Based on the financial report for Sep 30, 2024, Sartorius AG's Gross Profit amounts to 1.5B EUR.

What is Sartorius AG's Gross Profit growth rate?
Gross Profit CAGR 10Y
15%

Over the last year, the Gross Profit growth was -19%. The average annual Gross Profit growth rates for Sartorius AG have been -5% over the past three years , 10% over the past five years , and 15% over the past ten years .

Back to Top